Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Apr. 30, 2018	Mar. 31, 2025
Collaboration Agreement
Loss Contingencies [Line Items]
Aggregate payment of production facility		$ 135.0
Collaboration Agreement | BiBo Biopharma Engineering Co., Ltd.
Loss Contingencies [Line Items]
Additional percentage of milestone payment payable upon achievement		13.5
Collaboration Agreement | Research and Development | BiBo Biopharma Engineering Co., Ltd.
Loss Contingencies [Line Items]
Milestone payments		$ 121.5
BiBo Collaboration Agreement [Member]
Loss Contingencies [Line Items]
Agreement month and year		2024-04
Teva Agreements
Loss Contingencies [Line Items]
Payment upon achievement of certain clinical and commercial milestones	$ 65.0
Asset transfer and license agreement, termination period after written notice		120 days
Asset transfer and license agreement, termination period notice of breach		60 days
Asset transfer and license agreement termination notice period if bankruptcy petition filed		60 days
Asset transfer and license agreement termination notice period licensed patents and do not withdraw challenge		30 days
Teva Agreements | Teva's Development Program
Loss Contingencies [Line Items]
Payment upon achievement of certain clinical and commercial milestones	$ 2.5